WO2001028499A3 - A therapeutic mixture of hmg-coa reductase inhibitors - Google Patents

A therapeutic mixture of hmg-coa reductase inhibitors Download PDF

Info

Publication number
WO2001028499A3
WO2001028499A3 PCT/US2000/041304 US0041304W WO0128499A3 WO 2001028499 A3 WO2001028499 A3 WO 2001028499A3 US 0041304 W US0041304 W US 0041304W WO 0128499 A3 WO0128499 A3 WO 0128499A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
coa reductase
reductase inhibitors
therapeutic mixture
therapeutic
Prior art date
Application number
PCT/US2000/041304
Other languages
French (fr)
Other versions
WO2001028499A2 (en
Inventor
Wayne H Kaesemeyer
Original Assignee
Nitrosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitrosystems Inc filed Critical Nitrosystems Inc
Priority to MXPA02004021A priority Critical patent/MXPA02004021A/en
Priority to CA002388530A priority patent/CA2388530A1/en
Priority to AU21162/01A priority patent/AU2116201A/en
Priority to EP00984562A priority patent/EP1225885A4/en
Publication of WO2001028499A2 publication Critical patent/WO2001028499A2/en
Publication of WO2001028499A3 publication Critical patent/WO2001028499A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Therapeutic mixtures of statins alone or in combination with L-arginine are described herein.
PCT/US2000/041304 1999-10-19 2000-10-19 A therapeutic mixture of hmg-coa reductase inhibitors WO2001028499A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA02004021A MXPA02004021A (en) 1999-10-19 2000-10-19 A therapeutic mixture of hmg coa reductase inhibitors.
CA002388530A CA2388530A1 (en) 1999-10-19 2000-10-19 Therapeutic mixture of hmg-coa reductase inhibitors
AU21162/01A AU2116201A (en) 1999-10-19 2000-10-19 A therapeutic mixture of hmg-coa reductase inhibitors
EP00984562A EP1225885A4 (en) 1999-10-19 2000-10-19 A therapeutic mixture of hmg-coa reductase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42081699A 1999-10-19 1999-10-19
US09/420,816 1999-10-19

Publications (2)

Publication Number Publication Date
WO2001028499A2 WO2001028499A2 (en) 2001-04-26
WO2001028499A3 true WO2001028499A3 (en) 2001-10-04

Family

ID=23667961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/041304 WO2001028499A2 (en) 1999-10-19 2000-10-19 A therapeutic mixture of hmg-coa reductase inhibitors

Country Status (5)

Country Link
EP (1) EP1225885A4 (en)
AU (1) AU2116201A (en)
CA (1) CA2388530A1 (en)
MX (1) MXPA02004021A (en)
WO (1) WO2001028499A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
AU4013900A (en) 1999-03-19 2000-10-09 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
EP1865945A4 (en) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd Combination therapy for endothelial dysfunction, angina and diabetes
WO2014139469A1 (en) * 2013-03-15 2014-09-18 Wuhan Qr Science And Technology Development Co. Ornithine- or aspartate-containing compositions and the uses thereof
CN105246472B (en) * 2013-03-15 2018-10-12 武汉朗来科技发展有限公司 Composition containing ornithine and/or L-aminobutanedioic acid and its application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF PHARMACOLOGY, vol. 126, no. 5, March 1999 (1999-03-01), pages 1205 - 1213 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE, (BETHESDA, MD, USA); YADA ET AL.: "Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ singalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells", XP002938898, accession no. STN Database accession no. 1999219745 *
GUIJARRO ET AL.: "3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture", CIRCULATION RESEARCH, vol. 93, 1998, pages 490 - 500, XP002938896 *
See also references of EP1225885A4 *
WALTER SNEADER: "Drug prototypes and their exploitation", 1995, JOHN WILEY AND SONS LTD., XP002938897 *

Also Published As

Publication number Publication date
EP1225885A2 (en) 2002-07-31
CA2388530A1 (en) 2001-04-26
MXPA02004021A (en) 2004-08-23
AU2116201A (en) 2001-04-30
WO2001028499A2 (en) 2001-04-26
EP1225885A4 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
IL154977A0 (en) Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
IL191348A0 (en) Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
EP1193270A3 (en) Pyrrolobenzodiazepines
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
AU6580000A (en) Pharmaceutical compositions comprising a hmg reductase inhibitor
ZA200210103B (en) HMG-CoA reductase inhibitors and method.
HK1080734A1 (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
AU7761398A (en) Hmg-coa reductase inhibitor preparation process
AU2002214952A1 (en) Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
WO2001028499A3 (en) A therapeutic mixture of hmg-coa reductase inhibitors
AU1095695A (en) Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
AU1824201A (en) Polymorphisms in the human HMG-COA reductase gene
ZA985182B (en) Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer.
AU3324000A (en) Use of niaouli essential oil as transdermal permeation enhancer
AU5680900A (en) Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
GB2371748B (en) HMG-COA reductase inhibitor extended release formulation
AU2001280461A1 (en) Substituted pyrrole compounds and their use as spla2 inhibitors
AU3512900A (en) Novel thioredoxin family active site molecules and uses therefor
AU4578197A (en) Pharmaceutical compositions comprising hmg-coa reductase inhibitors, in particular fluvastatin
PL352106A1 (en) Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
AU2177701A (en) Use of hmg-coa reductase inhibitors for treating seborrhea

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/004021

Country of ref document: MX

Ref document number: 2388530

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000984562

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000984562

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000984562

Country of ref document: EP